Trial · NCT07307534
Nevus Removal vs. Conservative Treatment in Halo Nevus With Vitiligo: A Randomized Study
NCT07307534, Not applicable, Not yet recruiting, Xijing Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Nevus Removal vs. Conservative Treatment in Halo Nevus With Vitiligo: A Randomized Study. Trials, record NCT07307534. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07307534
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Nevus Removal vs. Conservative Treatment in Halo Nevus With Vitiligo: A Randomized Study
- NCT number
- NCT07307534
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Xijing Hospital
- Conditions
- Vitiligo, Halo Nevus
- Interventions
- Central Nevus Excision, The Standardized Medication Regimen
- First posted
- 2025-12-29
- Last updated
- 2026-01-15
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants Achieving VASl50 Response | From enrollment to the end of treatment at 6 months. | VASl (Vitiligo Area and Severity lndex) 50 response is defined as a 50% or greater reduction in VASl score from baseline. Assessment is conducted by trained dermatologists using standardized VASl scoring criteria. |
| Secondary | Percentage of Participants Achieving VASI75 and VASI90 responses at each follow-up time point | From enrollment to the end of treatment at 6 months. | VASl75 (or VASI90) response is defined as a 75% (or 90%) or greater reduction in VASl score from baseline. Assessment is conducted by trained dermatologists using standardized VASl scoring criteria. |
| Secondary | Change in Vitiligo Area and Severity Index (VASl) Score | From enrollment to the end of treatment at 6 months. | Calculate the difference between the VASl score at 6 months and the baseline VASl score, including the mean percentage change in VASI from baseline at 6 months. This reflects the improvement vitiligo area and severity over the treatment period. |
| Secondary | Change in Vitiligo Signs of Activity Score (VSAS) Score | From enrollment to the end of treatment at 6 months. | Calculate the difference between the VSAS score at 6 months and the baseline VSAS score. |
| Secondary | Change in Vitiligo Extent Score (VES) Score | From enrollment to the end of treatment at 6 months. | Calculate the difference between the VES score at 6 months and the baseline VES score. |
| Secondary | Change in Vitiligo European Task Force (VETF) Score | From enrollment to the end of treatment at 6 months. | Calculate the difference between the VETF score at 6 months and the baseline VETF score. |
| Secondary | Change in Dermatology life quality index (DLQI) Score | From enrollment to the end of treatment at 6 months. | Description \& Structure: Dermatology Life Quality Index (DLQI) is a 10-item, disease-specific quality of life questionnaire designed for adults with skin conditions. It assesses the impact of skin disease across three domains: Physical, Social, and Psychological impacts. Children Dermatology life quality index (CDLQI) is the children's version of the DLQI, which is suitable for children aged 5 to 16 years. For young children, parental assistance or proxy completion is recommended. Scoring Range: Each item is rated on a 4-point Likert scale (0 = "Not at all", 1 = "A little", 2 = "Quite a lot", 3 = "Very much"). The total score is the sum of all 10 items, ranging from 0 to 30. Score Direction \& Interpretation: A higher total score indicates a greater negative impact on the child's disease-specific quality of life (a worse outcome). A decrease in the score from baseline represents an improvement in quality of life. |
| Secondary | Change in The Vitiligo-specific Quality-of-Life instrument (VitiQoL) Score | From enrollment to the end of treatment at 6 months. | Description \& Structure: The VitiQoL is a 15-item, disease-specific quality of life questionnaire designed for patients with vitiligo. It comprises three subdomains: Psychological Burden, Activity Limitation, and Appearance Concerns. Patients are asked to recall their experience over the past week and rate how bothered they have been by each item on a 5-point Likert scale (0 = "Never", 1 = "Rarely", 2 = "Sometimes", 3 = "Often", 4 = "Always"). Scoring Range: The total score ranges from 0 to 60, calculated by summing the scores of all 15 items. Score Direction \& Interpretation: A higher total score indicates greater impairment in disease-specific quality of life (worse outcome). A decrease in score from baseline represents an improvement. |
| Secondary | Proportion of Participants Achieving investigator Global Assessment (lGA) Score lmprovement | From enrollment to the end of treatment at 6 months. | Assess participants' lGA scores at 24 weeks. Participants with an lGA score of "mild" or better (score s 2) are defined as achieving improvement, and the proportion is calculated. |
| Secondary | Incidence of Treatment-Emergent Adverse Events | From enrollment to the end of treatment at 6 months. | All surgery-related and disease-related adverse events, such as localized erythema, pruritus, scarring, and Koebner phenomenon, will be documented and analyzed, including their incidence, severity, and association with the interventions. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07307534
GET https://conductscience.org/api/trials/v1/NCT07307534/registered